25 Jun 2014

Puregon (Follitropine Bêta) - France

ATC: G03GA
GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
GONADOTROPINS AND OTHER OVULATION STIMULANTS
GONADOTROPINS
Puregon

Generic Matches for Follitropine Bêta (1)
Fertavid

Last Updated on 25 Jun 2014 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Puregon Indication

Chez les femmes adultes :
Puregon est indiqué pour le traitement de l’infertilité féminine dans les situations cliniques suivantes :
- Anovulation (y compris le syndrome des ovaires polykystiques - SOPK) chez les femmes ne répondant pas au traitement par le citrate de clomifène.
- Hyperstimulation ovarienne contrôlée pour induire le développement de follicules multiples dans le cadre des programmes de procréation médicalement assistée [par exemple, fécondation in vitro avec transfert d'embryon (FIVETE), transfert de gamètes dans les trompes (GIFT), injection intracytoplasmique de spermatozoïde (ICSI)].

Chez les hommes adultes :
- Déficience de la spermatogenèse due à un hypogonadisme hypogonadotrope.

Puregon Generic Name

Follitropine Bêta

Type

POM

Summary Product Characteristics (SPCs) Links
Résumé des Caractéristiques du Produit - Puregon (external site)

Related Learning Zones

Type 1 Childhood Diabetes CME

Type 1 Childhood Diabetes CME

In this EACCME-accredited online CME activity Individual Patient Management in Type 1 Childhood Diabetes, healthcare professionals will learn how to assess the psychosocial wellbeing of young patients with type 1 diabetes. 

Upon successful completion of this activity, healthcare professionals (such as endocrinologists, paediatricians, paediatric endocrinologists, diabetes specialists, specialist nurses, primary care physicians) will be awarded 1 European CME credit (ECMEC).

Type 2 Diabetes Knowledge Centre and CME

Type 2 Diabetes Knowledge Centre and CME

The Type 2 Diabetes Learning Zone comprises the Type 2 Diabetes Mellitus Knowledge Centre containing current epidemiology statistics, current diagnosis criteria from WHO and ADA, treatment options and latest guidelines; a Therapy Focus area compiling material on emerging insulin/incretin treatment combinations; and two free CME activities, which are the EACCME-accredited ‘Role of Newer Therapies for Type 2 Diabetes in Combination with Insulin’ (worth 1 CME credit) and ‘Best Practice in Type 2 Diabetes: Update on Incretin Therapies in Combination with Insulin’. 

Selected content related to Puregon (Follitropine Bêta)

Guidelines

Puregon Marketing Information

Puregon Generic Name
Follitropine Bêta
Marketing Company
Merck Sharp & Dohme Limited
Drug Type
POM
Date of Issue, Marketing Authority

03/05/1996

Médicaments utilisés en Endocrinologie et Diabète

Back to top